多空激战！有色韧性凸显，化工逆市冲锋，516020冲高3.45%！港股抄底时刻到了？南向资金连续3日百亿级爆买

Market Overview - A-shares experienced volatility on February 6, with the Shanghai Composite Index closing down 0.25% at 4065.58 points, and the ChiNext Index down 0.73% [1] - The overall market turnover decreased to 2.16 trillion yuan, marking a continuous six-day decline in trading volume [1] Sector Performance - The chemical and new energy sectors led the market, while the pharmaceutical sector showed relative resilience. Consumer goods experienced a pullback, and technology continued to be sluggish [1] - The chemical ETF (516020) saw a significant inflow of 199 billion yuan, with a daily gain of 2.37% after reaching a peak increase of 3.45% during the day [2][5][6][8] Chemical Sector Insights - The chemical sector is experiencing a strong upward cycle, driven by increased demand for lithium batteries and phosphorous chemicals, with key materials seeing a surge in prices [9][10] - Major stocks in the chemical sector, such as Enjie Co., Ltd. and Zhejiang Longsheng, reported significant gains, with some stocks rising over 6% [6][8] Non-Ferrous Metals Sector - The non-ferrous metals ETF (159876) demonstrated resilience, closing up 0.18% despite initial declines, supported by over 100 billion yuan in inflows [3][11] - The sector is expected to maintain high profitability over the next 3-5 years, driven by supply-demand dynamics and macroeconomic conditions [11] Hong Kong Market Dynamics - The Hong Kong market saw a significant influx of southbound capital, with purchases reaching 133.7 billion HKD, 249.8 billion HKD, and 148.6 billion HKD over three days [4] - The pharmaceutical sector in Hong Kong showed signs of recovery, with the Hong Kong Innovation Drug ETF (520880) rising by 2% during the day, driven by strong earnings forecasts from key companies [15][16] Investment Opportunities - Analysts suggest focusing on leading companies in the chemical sector and those benefiting from rising prices, with recommendations to invest through the chemical ETF (516020) for higher efficiency [10][21] - The Hong Kong Innovation Drug ETF (520880) and the Hong Kong Medical ETF (159137) are highlighted as attractive options for investors looking to capitalize on the pharmaceutical sector's growth [20][21]